Get the Stockscreener App
2.435
0.83%
0.02
Minerva Neurosciences Inc stock is traded at $2.435, with a volume of 11,072.
It is up +0.83% in the last 24 hours and up +22.98% over the past month.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
See More
Previous Close:
$2.415
Open:
$2.47
24h Volume:
11,072
Relative Volume:
0.49
Market Cap:
$17.03M
Revenue:
-
Net Income/Loss:
$-33.65M
P/E Ratio:
-0.5472
EPS:
-4.45
Net Cash Flow:
$-20.83M
1W Performance:
+8.22%
1M Performance:
+22.98%
6M Performance:
+33.79%
1Y Performance:
-5.98%
1-Day Range:
$2.415
$2.4713
1-Week Range:
$2.205
$2.60
52-Week Range:
$1.15
$3.00
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1601 TRAPELO ROAD, WALTHAM, MA
Compare NERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
2.435 | 17.06M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
What to expect from Minerva Neurosciences Inc. in the next 30 daysOil Prices & Precise Buy Zone Identification - Newser
Evaluating Minerva Neurosciences Inc. with trendline analysisJuly 2025 Movers & Daily Risk Controlled Trade Plans - Newser
How institutional ownership impacts Minerva Neurosciences Inc. stockAnalyst Upgrade & Verified Swing Trading Watchlists - Newser
Trend analysis for Minerva Neurosciences Inc. this weekTrade Entry Report & AI Forecasted Entry/Exit Points - Newser
What earnings revisions data tells us about Minerva Neurosciences Inc.Weekly Trend Report & AI Enhanced Market Trend Forecasts - Newser
What institutional flow reveals about Minerva Neurosciences Inc.Portfolio Update Report & Stepwise Trade Signal Guides - Newser
Is Minerva Neurosciences Inc. building a consolidation baseTrade Volume Summary & Safe Entry Zone Tips - Newser
Can swing trading help recover from Minerva Neurosciences Inc. lossesJuly 2025 Analyst Calls & Accurate Intraday Trade Tips - Newser
Key metrics from Minerva Neurosciences Inc.’s quarterly data2025 Dividend Review & Weekly Top Gainers Alerts - Newser
Is Minerva Neurosciences Inc. showing signs of accumulation2025 Market Outlook & Fast Momentum Stock Entry Tips - Newser
Can Minerva Neurosciences Inc. recover in the next quarterDay Trade & Technical Pattern Based Signals - Newser
Can volume confirm reversal in Minerva Neurosciences Inc.July 2025 Catalysts & Reliable Momentum Entry Alerts - Newser
What MACD and RSI say about Minerva Neurosciences Inc.Market Sentiment Summary & Accurate Buy Signal Alerts - Newser
Tools to assess Minerva Neurosciences Inc.’s risk profileMarket Performance Report & Technical Pattern Recognition Alerts - Newser
Why is Minerva Neurosciences Inc. stock going upMarket Risk Analysis & Advanced Technical Signal Analysis - mustnews.co.kr
Top chart patterns to watch in Minerva Neurosciences Inc.July 2025 Movers & Smart Allocation Stock Reports - Newser
What’s next for Minerva Neurosciences Inc. stock priceJuly 2025 Review & Capital Protection Trading Alerts - Newser
Is Minerva Neurosciences Inc. Stock a Smart Buy in 2025 Investment Analysis InsideEarnings Beat & Free Low Drawdown Momentum Trade Ideas - Newser
Is Minerva Neurosciences Inc. stock good for income investorsJuly 2025 Market Mood & Safe Capital Growth Trade Ideas - thegnnews.com
How cyclical is Minerva Neurosciences Inc.’s revenue streamJuly 2025 EndofMonth & Community Consensus Trade Signals - 선데이타임즈
Using economic indicators to assess Minerva Neurosciences Inc. potentialGDP Growth & Weekly Top Gainers Trade List - Newser
Will Minerva Neurosciences Inc. outperform the market2025 Top Decliners & Entry Point Confirmation Alerts - Newser
Minerva Neurosciences Faces Regulatory Hurdle with FDA Mandated Trial for Roluperidone, Reports Q2 Loss and Low Cash Position - AInvest
Minerva's 20% Surge: Earnings Spark Volatility Amid Biotech Sector Divergence - AInvest
Minerva Neurosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Why HUMAW stock attracts strong analyst attentionOil Prices & Capital Protection Trade Alerts - Newser
Minerva Neurosciences: Q2 Earnings Snapshot - Greenwich Time
P 500Earnings Performance Report & Fast Entry Momentum Trade Alerts - Newser
Minerva Neurosciences Reports Q2 2025 Financial Results - TipRanks
Volume Profile Shows Strong Base for Minerva Neurosciences Inc.July 2025 Movers & Risk Controlled Swing Alerts - sundaytimes.kr
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results - GlobeNewswire
FDA Demands New 52-Week Trial from Minerva as Cash Position Drops to $15.3M, Company Explores Sale - Stock Titan
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):